• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

    11/14/24 9:21:21 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SKYE alert in real time by email
    SC 13G/A 1 sb-sc13ga_093024.htm AMENDMENT TO FORM SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Skye Bioscience, Inc.

    (Name of Issuer)

     
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

     

    83086J200

    (CUSIP Number)

     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 2 of 9

     

    CUSIP No.    83086J200    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,315,146 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,315,146 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,315,146 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.3%(1)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

     

    (1)Based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 3 of 9

     

    CUSIP No. 83086J200    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,315,146 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,315,146 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,315,146 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.3%(1)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    (1)Based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 4 of 9

     

    CUSIP No. 83086J200    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,315,146 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,315,146 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,315,146 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.3%(1)

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

     
    (1)Based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 5 of 9

     

    CUSIP No. 83086J200    

     

    Item 1(a).   Name of Issuer: Skye Biosciences, Inc. (the “Issuer”)
         
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:   

    11250 El Camino Real, Suite 100
    San Diego, California 92130

         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.001 per share (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 83086J200
         
    Item 3.   If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

    Page 6 of 9

     

    CUSIP No. 83086J200    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

      

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 7 of 9

     

    CUSIP No. 83086J200    

      

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: November 14, 2024  
         
     

    Altium Capital Management, LP 

     

     
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
         
      By: Altium Growth GP, LLC  
      Its: General Partner  
           
      Signature:   /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC  
       
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     

     

      

    Page 8 of 9

     

    EXHIBIT INDEX 

     

    EXHIBIT 1:Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

     

    Get the next $SKYE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SKYE

    DatePrice TargetRatingAnalyst
    10/6/2025$2.00Buy → Hold
    Craig Hallum
    10/6/2025$2.00Overweight → Neutral
    Cantor Fitzgerald
    8/15/2025$10.00Outperform
    Evercore ISI
    2/28/2025Outperform
    William Blair
    9/30/2024$20.00Sector Outperform
    Scotiabank
    9/10/2024$15.00Mkt Outperform
    JMP Securities
    7/9/2024$18.00Buy
    Craig Hallum
    5/23/2024$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SKYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schwab Andrew J. sold $800,548 worth of shares (231,405 units at $3.46) (SEC Form 4)

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    8/22/25 7:07:28 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner 5am Partners Vii, Llc sold $800,548 worth of shares (231,405 units at $3.46) (SEC Form 4)

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    8/22/25 7:05:36 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Twitty Christopher claimed ownership of 81,242 shares (SEC Form 3)

    3 - Skye Bioscience, Inc. (0001516551) (Issuer)

    4/25/25 4:03:41 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SKYE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Skye Bioscience to Participate in Upcoming Investment Conferences

    San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:Citi Global Healthcare Conference (Miami)1x1 meetings: Dec. 2Evercore Annual Healthcare Conference (Coral Gables)Fireside Chat: Dec. 3, 12:55 pm ET1x1 meetingsPiper Sandler Annual Healthcare Conference (New York)Fireside Chat: Dec. 4, 11:30 am ET1x1 meetings Available webcasts will be accessible on Skye's website.About Skye Bioscience Skye is focused on unlocking new therapeutic pathways

    11/24/25 7:00:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

    Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events.Nimacimab plus semaglutide showed additional reduction in waist circumference of -3.2 cm vs. semaglutide alone.Rebound weight gain was lower in the 12-week post-treatment follow-up period in patients treated with nimacimab plus semaglutide vs. semaglutide alone. SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biotechnology compa

    11/10/25 4:01:00 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

    SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will present a late-breaking oral presentation at ObesityWeek 2025 on November 7, 2025, in Atlanta, Georgia. The presentation will highlight recent topline data from CBeyond™, a Phase 2 proof-of-concept study of nimacimab, Skye's peripherally-restricted CB1 inhibitor antibody. New data from an analysis of participants 12 weeks post-treatment demonstrated that nimacimab 200 mg (subcutaneous, weekly) plus semaglutide blunted rebound weight gain

    11/5/25 7:05:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SKYE
    SEC Filings

    View All

    Skye Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Skye Bioscience, Inc. (0001516551) (Filer)

    11/10/25 4:10:06 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Skye Bioscience Inc.

    10-Q - Skye Bioscience, Inc. (0001516551) (Filer)

    11/10/25 4:09:18 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Skye Bioscience, Inc. (0001516551) (Filer)

    10/6/25 8:18:06 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SKYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Skye Bioscience downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Skye Bioscience from Buy to Hold and set a new price target of $2.00

    10/6/25 12:17:16 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Skye Bioscience from Overweight to Neutral and set a new price target of $2.00

    10/6/25 10:31:53 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on Skye Bioscience with a new price target

    Evercore ISI initiated coverage of Skye Bioscience with a rating of Outperform and set a new price target of $10.00

    8/15/25 8:20:07 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SKYE
    Financials

    Live finance-specific insights

    View All

    Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

    Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events.Nimacimab plus semaglutide showed additional reduction in waist circumference of -3.2 cm vs. semaglutide alone.Rebound weight gain was lower in the 12-week post-treatment follow-up period in patients treated with nimacimab plus semaglutide vs. semaglutide alone. SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biotechnology compa

    11/10/25 4:01:00 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

    SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes

    11/5/25 7:00:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

    Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.Clinically meaningful additional weight loss observed with combination of nimacimab, a peripheral CB1 inhibitor, and semaglutide compared to semaglutide alone.Nimacimab alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and no nimacimab-associated neuropsychiatric adverse events reported.Company to host conference call today at 8:00 a.m. ET. SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:S

    10/6/25 7:00:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SKYE
    Leadership Updates

    Live Leadership Updates

    View All

    Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

    Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product' strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma's recently announced €38 million Series C financing Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM a

    10/28/25 8:00:00 AM ET
    $CNTX
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

    SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli

    9/3/24 7:00:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

    SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi

    8/9/24 5:59:37 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SKYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

    SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)

    11/14/24 10:02:54 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

    SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)

    11/14/24 9:21:21 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Skye Bioscience Inc.

    SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)

    8/14/24 4:59:17 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care